3-氟二苯并[b,e]氧杂卓-11(6H)-酮 | 114312-48-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 中文名称: 3-氟二苯并[b,e]氧杂卓-11(6H)-酮
• 中文别名: 3-氟二苯并[B,E]氧杂卓-11(6H)-酮
• 英文名称: 3-fluoro-6,11-dihydro-dibenzo[b,e]oxepin-11-one
• 英文别名: 3-Fluoro-6,11-dihydrodibenzoxepin-11-one；3-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-one；3-fluoro-6H-dibenzo[b,e]oxepin-11-one；3-Fluorodibenz[b,e]oxepin-11(6H)-one；3-fluoro-6H-benzo[c][1]benzoxepin-11-one
• CAS: 114312-48-0
• 化学式: C₁₄H₉FO₂
• 分子量: 228.223
• InChiKey: BZAIXEGWNRZEFA-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81℃
• 密度：
  1.299±0.06 g/cm3 (20℃ 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氟二苯并[b,e]氧杂卓-11(6H)-酮 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 10.5h， 生成
  参考文献：
  名称：

  Synthesis and Biological Activity of 11-(4-(Cinnamyl)-1-piperazinyl)-6,11-dihydrodibenz(b,e)oxepin Derivatives, Potential Agents for the Treatment of Cerebrovascular Disorders.

  摘要：

  合成了一系列11-[4-（肉桂基）-1-哌嗪基]-6，11-二氢二苯并[b，e]氧芴及其相关化合物，并评价了它们对完全缺血、常压缺氧、脂质过氧化和惊厥的保护活性。通过对这一系列化合物的构效关系研究，发现了（E）-1-（3-氟-6，11-二氢二苯并[b，e]氧芑-11-基）-4-（3-苯基-2-丙烯基）哌嗪二马来酸盐（50），AJ-3941，它具有最适合的联合药理活性。

  DOI：

  10.1248/cpb.39.2564
• 作为产物：
  描述：

  3-氟苯酚 在 sodium hydride 作用下， 以 环丁砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 3-氟二苯并[b,e]氧杂卓-11(6H)-酮
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo[a,d]cycloheptan-5-ones:  Novel p38 MAP Kinase Inhibitors

  摘要：

  The pathogenesis of chronic inflammatory diseases is promoted by various pro-inflammatory cytokines. p38 MAP kinase seems to be a valid target as it controls proinflammatory cytokine levels on both transcriptional and translational levels. Starting from benzophenone-type inhibitors, a rigidisation strategy lead to 3-amino-6,11-dihydro-dibenzo[b,e]thiepin-11-one, phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones, and dibenzo[a,d]cyclohepten-5-ones. Synthesis, p38 inhibition, and CYP-inhibition of selected compounds are described.

  DOI：

  10.1021/jm061072p

文献信息

• Dibenz[b,e]oxepin derivatives and pharmaceutical composition containing
  申请人：Dainippon Pharmaceutical Co., Ltd.

  公开号：US04889858A1

  公开（公告）日：1989-12-26

  The present invention relates to compounds represented by the general formula (I): ##STR1## wherein R.sub.1 is H or methoxy, R.sub.2 is H, methoxy, OH or F, R.sub.3 is H or F, R.sub.4 is H or F at 7-, 8- or 9-position, and .circle.Ar is a benzene, thiophene or pyridine ring, provided that (i) at least two of R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are H, (ii) R.sub.2 or R.sub.3 is F when R.sub.4 is F, (iii) R.sub.1, R.sub.3 and R.sub.4 are H when R.sub.2 is methoxy or OH, (iv) R.sub.2 and R.sub.3 are not simultaneously F, and (v) R.sub.2 and R.sub.3 are H or F, and both R.sub.1 and R.sub.4 are H when .circle.Ar is a thiophene or pyridine ring, or a physiologically acceptable acid addition salt thereof. The compounds of the present invention have an excellent protective effect against cerebral anoxia and some of them have also an inhibitory effect on lipid peroxidation of mitochondrial membrane of brain and an anti-convulsant activity and are useful as an agent for prevention or treatment of cerebral diseases caused by hypoxia in mammals including human.

  本发明涉及由通式（I）表示的化合物：其中R.sub.1为H或甲氧基，R.sub.2为H、甲氧基、羟基或氟，R.sub.3为H或氟，R.sub.4为7-、8-或9-位的H或氟，.circle.Ar为苯、噻吩或吡啶环，前提是（i）至少两个R.sub.1、R.sub.2、R.sub.3和R.sub.4中的H，（ii）当R.sub.4为F时，R.sub.2或R.sub.3为F，（iii）当R.sub.2为甲氧基或羟基时，R.sub.1、R.sub.3和R.sub.4为H，（iv）R.sub.2和R.sub.3不同时为F，（v）R.sub.2和R.sub.3为H或F，当.circle.Ar为噻吩或吡啶环时，R.sub.1和R.sub.4均为H，或其生理上可接受的酸盐。本发明的化合物对大脑缺氧有良好的保护作用，其中一些化合物还具有抑制脑线粒体膜脂质过氧化和抗惊厥活性，可用作预防或治疗包括人类在内的哺乳动物由缺氧引起的脑部疾病的药物。
• [EN] TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS<br/>[FR] MODULATEURS TRICYCLIQUES DU RECEPTEUR NUCLEAIRE DE L'HORMONE STEROIDE
  申请人：LILLY CO ELI

  公开号：WO2005066161A1

  公开（公告）日：2005-07-21

  The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

  本发明提供了化合物的公式(I)：或其药学上可接受的盐；包含公式(I)化合物的有效量与适当载体、稀释剂或赋形剂组合的药物组合物；以及治疗生理紊乱的方法，特别是充血性心脏病、高血压、类风湿性关节炎或炎症，包括向患者施用公式(I)化合物的有效量。
• A Parham cyclization approach to diaryl-fused seven-membered ring heterocyclic ketones
  作者：John Farrokh、Catherine Campos、David A. Hunt

  DOI：10.1016/j.tetlet.2015.07.043

  日期：2015.9

  described. This work describes a novel synthesis route to diaryl-fused seven membered heterocyclic ketones through the generation of functionalized aryllithiums by bromine–lithium exchange, followed by intramolecular cyclization onto an electrophilic nitrile functional group. The resulting N-lithioimine can then be hydrolyzed to the desired ketone, generally in good yields. The order of addition of

  芳基稠合的七元杂环骨架出现在各种药学上相关的化合物中。但是，仅描述了很少的制备方法。这项工作描述了一种新颖的合成路线，该路线是通过溴-锂交换生成官能化的芳基锂，然后分子内环化成亲电子腈官能团，从而生成二芳基稠合的七元杂环酮的新型合成途径。然后可以通常以高收率将所得的N-硫代亚氨基亚胺水解成所需的酮。正丁基锂的添加顺序对于该方法至关重要，事实证明，反向添加可以减轻副产物的形成并提高产率。
• Tricyclic steroid hormone nuclear receptor modulators
  申请人：Gavardinas Konstantinos

  公开号：US20070037788A1

  公开（公告）日：2007-02-15

  The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

  本发明提供了公式(I)的化合物或其药学上可接受的盐；包括公式(I)的化合物与适当的载体、稀释剂或赋形剂组合的有效量的制药组合物；以及治疗生理紊乱，特别是充血性心脏病、高血压、类风湿性关节炎或炎症的方法，包括向患者中投与公式(I)的化合物的有效量。
• Dibenzocycloheptane compounds and pharmaceuticals containing these compounds
  申请人：Laufer Stefan

  公开号：US20090105327A1

  公开（公告）日：2009-04-23

  The present invention relates to compounds of the formula I in which R1, R2, R3, R4, X and Y have the meanings indicated in the description. These compounds have immunomodulating effects, as well as an inhibiting or regulating effect on the release of IL-1β and/or TNF-α. They can therefore be used for the treatment of diseases associated with a disturbance of the immune system.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、X和Y具有描述中所示的含义。这些化合物具有免疫调节作用，以及对IL-1β和/或TNF-α的释放具有抑制或调节作用。因此，它们可用于治疗与免疫系统紊乱相关的疾病。